Showing results (2051-2060 of 2,238) with videos related to
Sort By:
Pageof 224
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.Annals of Surgical Oncology|May 27, 2026
The Role of PD-L1 in Treatment Decision-Making for Perioperative EGFR-Mutated Lung Cancer and its Genomic AnalysisYi-Fan Qi, Zhen-Bin Qiu, Wei-Ye Huang, et al.The Lancet. Oncology|July 11, 2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, et al.Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA TrialThomas John, Christian Grohé, Jonathan W Goldman, et al.The Journal of Clinical Investigation|July 1, 2022
Lymph node fibroblastic reticular cells preserve a tolerogenic niche in allograft transplantation through laminin α4Lushen Li, Marina W Shirkey, Tianshu Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationJin-Ji Yang, Xu-Chao Zhang, Jian Su, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.NPJ Precision Oncology|September 19, 2022
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysisChao Zhang, Hua-Fei Chen, Shi Yan, et al.Pageof 224